A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

John Thomas Barrett, Bruno Orofiamma, Janardan D. Khandekar, Paul P. Carbone, Robert L. Comis, Thomas E. Davis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

Original languageEnglish (US)
Pages (from-to)2445-2447
Number of pages3
JournalCancer
Volume64
Issue number12
DOIs
StatePublished - Dec 15 1989
Externally publishedYes

Fingerprint

Mitoguazone
Vinblastine
Transitional Cell Carcinoma
Urinary Tract
Drug-Related Side Effects and Adverse Reactions
Cisplatin
Confidence Intervals
Drug Therapy
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract. / Barrett, John Thomas; Orofiamma, Bruno; Khandekar, Janardan D.; Carbone, Paul P.; Comis, Robert L.; Davis, Thomas E.

In: Cancer, Vol. 64, No. 12, 15.12.1989, p. 2445-2447.

Research output: Contribution to journalArticle

Barrett, John Thomas ; Orofiamma, Bruno ; Khandekar, Janardan D. ; Carbone, Paul P. ; Comis, Robert L. ; Davis, Thomas E. / A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract. In: Cancer. 1989 ; Vol. 64, No. 12. pp. 2445-2447.
@article{3e4bbb87092445809b22e6b2dcf3fa18,
title = "A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract",
abstract = "This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11{\%}) on MGBG had partial remission (95{\%} confidence interval: 0.01, 0.35), whereas four of 20 (20{\%}) responded on the VLB arm (95{\%} confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46{\%} of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.",
author = "Barrett, {John Thomas} and Bruno Orofiamma and Khandekar, {Janardan D.} and Carbone, {Paul P.} and Comis, {Robert L.} and Davis, {Thomas E.}",
year = "1989",
month = "12",
day = "15",
doi = "10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J",
language = "English (US)",
volume = "64",
pages = "2445--2447",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - A phase II study of mitoguazone and vinblastine in advanced transitional cell carcinoma of the urinary tract

AU - Barrett, John Thomas

AU - Orofiamma, Bruno

AU - Khandekar, Janardan D.

AU - Carbone, Paul P.

AU - Comis, Robert L.

AU - Davis, Thomas E.

PY - 1989/12/15

Y1 - 1989/12/15

N2 - This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

AB - This is a comparative study to evaluate response rate to mitoguazone (MGBG) and vinblastine (VLB) in 52 evaluable patients with advanced transitional cell carcinoma of the urinary tract. Of 38 patients with measurable disease, two of 18 (11%) on MGBG had partial remission (95% confidence interval: 0.01, 0.35), whereas four of 20 (20%) responded on the VLB arm (95% confidence level: 0.06–0.44). Both responses on the MGBG arm were seen in patients given prior chemotherapy. Side effects of both drugs were significant, with 46% of patients given VLB developing severe or life‐threatening hematologic toxicity. Data indicate that both drugs, as single agents, are probably inferior to cisplatin for control of advanced transitional cell carcinoma of the urinary tract. Cancer 64:2445–2447, 1989.

UR - http://www.scopus.com/inward/record.url?scp=0024815720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024815720&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J

DO - 10.1002/1097-0142(19891215)64:12<2445::AID-CNCR2820641208>3.0.CO;2-J

M3 - Article

C2 - 2684384

AN - SCOPUS:0024815720

VL - 64

SP - 2445

EP - 2447

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -